the expression of PD-L1 induces an immuno-suppressive effect to protect cancer cells from immune elimination, which designates PD-L1 as an important target for immunotherapy. However, little is known about the regulation mechanism and the function of PD-L1 in lung cancer...
After permeabilization, the sections were stained with vinculin polyclonal antibody (Proteintech, Wuhan, China) and Alexa488-conjugated or Cy5-conjugated anti-rabbit IgG antibody (Servicebio, Wuhan, China). The number of focal adhesions in the cells was counted by using ImageJ software. ...
The anti-IL4I1 antibody (1:200, Abcam, ab176588) and anti-CD206 (1:1000, Proteintech, China) were respectively utilized to detect expression levels of IL4I1 and CD206 in different tissues. Cell culture and siRNA interference assay Human renal proximal tubular epithelial cell line (HK2) ...
IHC: Anti-CCL19 antibody produced in rabbit Sigma Cat# HPA067758; RRID: AB_2685897 IHC: CD11c/Integrin Alpha X Monoclonal Proteintech Cat# 60258-1-Ig; RRID: AB_2881379 IHC: CD8α Rabbit mAb CST Cat# 98941S; RRID: AB_2756376 IHC: Rabbit monoclonal to Granzyme B Abcam Cat# ab255598; ...
6d). However, when the activated T cells were pre-incubated with an anti-PD-1 antibody prior to co-culturing with rS100A9-treated THP-1 cells, a remarkable restoration of T cell proliferation was observed (Fig. 6e). Furthermore, we observed a constant decrease in the expression levels of...
Hsc70 promotes lysosomal degradation of PD-L1 ICI using anti-PD-L1 antibody (aPD-L1) can trigger PD-L1 internalization and recycling. In this study, we confirmed this process in 4T1 breast cancer cells, showing that PD-L1 expression on the cell membrane significantly decreased after short-ter...
Cancer expression of PD-L1 suppresses anti-tumor immunity. PD-L1 has emerged as a remarkable therapeutic target. However, the regulation of PD-L1 degradation is not understood. Here, we identify several compounds as inducers of PD-L1 degradation using a
Since NEK2 regulates the stability of PD-L1, we hypothesized that inhibition of NEK2 may enhance the therapeutic efficacy of PD-L1-targeted drugs. Indeed, NEK2 inhibitor plus anti-PD-L1 antibody significantly improved the T cell-mediated cytotoxic effect in vitro compared with mono-NEK2 inhibito...
By analyzing PRMT3 expression in HCC patients who received immunotherapy, we found that PRMT3 was notably higher in tumor samples from patients who received anti-PD-1/PD-L1 therapy at both mRNA and protein levels than in tumor samples from patients who did not (Fig.2A, Band Supplementary ...
(PD-L1) pathway have achieved remarkable success in the treatment of various malignancies including advanced HCC2. Nevertheless, anti-PD-1/PD-L1 monotherapy induces durable responses in only a subset of cancer patients and some responders relapse after a period of response3. Abnormal tumor blood ...